JAMA Neurol:利妥昔单抗治疗新发全身性重症肌无力

2020-05-06 MedSci原创 MedSci原创

利妥昔单抗治疗新发全身性重症肌无力的临床疗效显著优于常规免疫抑制剂

近日研究人员评估了利妥昔单抗治疗难治性和新发全身性重症肌无力的疗效,并与常规免疫疗法进行了比较。
 
本次研究为回顾性队列研究,前瞻性地收集了瑞典斯德哥尔摩卡罗琳大学医院患者数据,包括72名重症肌无力患者,患者随机接受低剂量利妥昔单抗治疗(通常每6个月500毫克)或常规免疫抑制剂治疗。研究考察缓解时间(主要结果)以及使用抢救疗法或附加免疫疗法和缓解时间(次要结果)。
 
在72名患者中,31名患者(43%)为女性,治疗开始时的平均年龄(SD)为60(18)岁。24例患者在发病12个月内接受了利妥昔单抗治疗,总计48例患者接受了利妥昔单抗治疗,其中34例患有难治性疾病。总计26名患者(3名[12%]女性;治疗开始时平均[SD]年龄68[11]岁)接受常规免疫抑制剂治疗。新发患者相对难治性疾病患者的中位缓解时间较短(7个月 vs 16个月:危险比[HR],2.53),利妥昔单抗相比于常规免疫抑制剂,治疗中位缓解时间较短(7个月vs 11个月:HR:2.97)。此外,利妥昔单抗组在头24个月内需要的抢救性治疗次数较少(平均值[SD],0.38[1.10]vs1.31[1.59]次;平均差:-1.26),并且更多的患者很少或不需要额外的免疫治疗(70%vs35%;OR:5.47)。利妥昔单抗与常规疗法相比,因不良事件导致的停药率较低(3%vs46%)。
 
研究认为,利妥昔单抗治疗新发全身性重症肌无力的临床疗效显著优于常规免疫抑制剂。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2001049, encodeId=250b20010492e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Dec 29 20:09:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904292, encodeId=d5f790429253, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=lifefamily, createdTime=Wed Dec 02 13:29:46 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660488, encodeId=0cf91660488e7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Wed Nov 11 06:09:35 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957384, encodeId=e2e1195e3842d, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29686, encryptionId=361f296867a, topicName=全身性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Jul 15 10:09:35 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436669, encodeId=427f143666951, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 08 10:09:35 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036081, encodeId=a4f51036081a0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed May 06 22:09:35 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2001049, encodeId=250b20010492e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Dec 29 20:09:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904292, encodeId=d5f790429253, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=lifefamily, createdTime=Wed Dec 02 13:29:46 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660488, encodeId=0cf91660488e7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Wed Nov 11 06:09:35 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957384, encodeId=e2e1195e3842d, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29686, encryptionId=361f296867a, topicName=全身性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Jul 15 10:09:35 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436669, encodeId=427f143666951, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 08 10:09:35 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036081, encodeId=a4f51036081a0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed May 06 22:09:35 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2001049, encodeId=250b20010492e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Dec 29 20:09:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904292, encodeId=d5f790429253, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=lifefamily, createdTime=Wed Dec 02 13:29:46 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660488, encodeId=0cf91660488e7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Wed Nov 11 06:09:35 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957384, encodeId=e2e1195e3842d, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29686, encryptionId=361f296867a, topicName=全身性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Jul 15 10:09:35 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436669, encodeId=427f143666951, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 08 10:09:35 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036081, encodeId=a4f51036081a0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed May 06 22:09:35 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2001049, encodeId=250b20010492e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Dec 29 20:09:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904292, encodeId=d5f790429253, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=lifefamily, createdTime=Wed Dec 02 13:29:46 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660488, encodeId=0cf91660488e7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Wed Nov 11 06:09:35 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957384, encodeId=e2e1195e3842d, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29686, encryptionId=361f296867a, topicName=全身性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Jul 15 10:09:35 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436669, encodeId=427f143666951, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 08 10:09:35 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036081, encodeId=a4f51036081a0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed May 06 22:09:35 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2001049, encodeId=250b20010492e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Dec 29 20:09:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904292, encodeId=d5f790429253, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=lifefamily, createdTime=Wed Dec 02 13:29:46 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660488, encodeId=0cf91660488e7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Wed Nov 11 06:09:35 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957384, encodeId=e2e1195e3842d, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29686, encryptionId=361f296867a, topicName=全身性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Jul 15 10:09:35 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436669, encodeId=427f143666951, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 08 10:09:35 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036081, encodeId=a4f51036081a0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed May 06 22:09:35 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2001049, encodeId=250b20010492e, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Tue Dec 29 20:09:35 CST 2020, time=2020-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904292, encodeId=d5f790429253, content=<a href='/topic/show?id=910e959e0c9' target=_blank style='color:#2F92EE;'>#重症肌无力#</a>的<a href='/topic/show?id=5a8be955621' target=_blank style='color:#2F92EE;'>#罕见病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95970, encryptionId=910e959e0c9, topicName=重症肌无力), TopicDto(id=79556, encryptionId=5a8be955621, topicName=罕见病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=lifefamily, createdTime=Wed Dec 02 13:29:46 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660488, encodeId=0cf91660488e7, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32285, encryptionId=c0de32285a1, topicName=利妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a58d25117340, createdName=花花1374, createdTime=Wed Nov 11 06:09:35 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957384, encodeId=e2e1195e3842d, content=<a href='/topic/show?id=361f296867a' target=_blank style='color:#2F92EE;'>#全身性重症肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29686, encryptionId=361f296867a, topicName=全身性重症肌无力)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Wed Jul 15 10:09:35 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436669, encodeId=427f143666951, content=<a href='/topic/show?id=e7c18092578' target=_blank style='color:#2F92EE;'>#肌无力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80925, encryptionId=e7c18092578, topicName=肌无力)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri May 08 10:09:35 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036081, encodeId=a4f51036081a0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed May 06 22:09:35 CST 2020, time=2020-05-06, status=1, ipAttribution=)]
    2020-05-06 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Blood:既往20余年结节性淋巴细胞为主型霍奇金淋巴瘤的治疗预后

以RT/CMT作为I-II期NLPHL患者的前期治疗或可提高患者的PFS。

邱录贵教授:利妥昔单抗是淋巴瘤免疫化疗的“基石”药物,为惰性B细胞淋巴瘤带来显著生存获益丨2020年白血病·淋巴瘤高峰论坛

邱录贵教授编者按:2020年1月11~12日,“CSCO抗白血病联盟&抗淋巴瘤联盟工作会议暨2020年白血病·淋巴瘤高峰论坛”在美丽的沿海城市深圳市隆重召开,汇聚了国内外血液肿瘤的众多专家及学者,共同探讨白血病及淋巴瘤领域的诸多进展。利妥昔单抗(rituximab)是首个应用于肿瘤治疗的CD20单抗,在B细胞淋巴瘤的治疗中具有关键的价值,同时利妥昔单抗+CHOP方案也是弥漫大B细胞淋巴

辉瑞的美罗华(利妥昔单抗)仿制药Ruxience,获得欧盟批准

Ruxience被批准用于治疗非霍奇金淋巴瘤(NHL)、慢性淋巴细胞性白血病(CLL)、类风湿性关节炎(RA)、肉芽肿伴多血管炎(GPA)和显微多血管炎(MPA)和寻常型天疱疮(PV)。

Cell Death Dis:新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤

CD20缺失是复发性/难治愈性的弥漫性大B细胞淋巴瘤(DLBCL)采用利妥昔单抗相关方案再治疗的主要障碍。组蛋白去乙酰化会导致基因沉默,抑制CD20的表达。西达本胺(Chidamide)是组蛋白脱乙酰基酶(HDACs)的一种新型抑制剂。研究人员预测西达本胺可以预防利妥昔单抗介导的CD20表达下调并促进利妥昔单抗诱导的杀伤作用。本研究主要是通过构建内外源模型来研究西达本胺与利妥昔单抗在DLBCL中的

英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤

英国国家健康与护理卓越研究所(NICE)宣布推荐将Celgene的Revlimid(来那度胺)与Roche的MabThera(利妥昔单抗)组合用于先前已治疗过的滤泡性淋巴瘤患者,为大约900名患者提供了新的选择。

关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则(征求意见稿)》意见的通知

利妥昔单抗注射液由Genentech公司原研,2000年在中国上市,商品名为美罗华。目前,多家国内外制药企业加入其生物类似药的研发。为进一步明确技术审评标准,提高企业研发效率,在原国家食品药品监督管理